fda probability, page-7

After hitting the market in 1999, a 2007 study in the New England Journal of Medicine linked Avandia to a 43 percent increased risk of heart attack, and a 64 percent higher risk of cardiovascular death, compared to patients treated with other methods!

There were many articles and reviews published about Avandia following the New England Journal of Medicine study, but research from the Mayo Clinic revealed that 90 percent of scientists who wrote favorable articles about the drug had financial ties to GlaxoSmithKline.

Unfortunately, a committee of independent experts still recommended that Avandia remain on the market, despite its many risks, and a U.S. Food and Drug Administration (FDA) oversight board voted 8 to 7 to accept the advice. http://articles.mercola.com/sites/articles/archive/2011/12/01/glaxosmithkline-to-pay-damages-for-avandia.aspx?e_cid=20111201_DNL_art_1 Does this help with your question?